Modern concepts of antiretroviral therapy in children with HIV infection
https://doi.org/10.22328/2077-9828-2025-17-3-9-30
Abstract
The lecture, based on international and our own scientific and clinical experience, examines aspects of epidemiology, features of clinical manifestations, diagnostics, and treatment of HIV infection in children. It covers complex issues related to the study of adverse events associated with the use of antiretroviral drugs, disorders of various organs and systems directly or indirectly related to the effects of HIV, drugs, and comorbid pathological processes. It presents materials related to the problem of cardiovascular diseases, the risk of which in children increases with age, the duration of HIV infection, and the duration of antiretroviral therapy. It emphasizes the importance of metabolic disorders (impaired lipid and glucose metabolism), the role of endothelial cell damage and dysfunction of the vascular endothelium of the heart and brain in the early development of cardiovascular diseases in children, and proposes an algorithm for providing assistance to children with HIV infection and dyslipidemia during antiretroviral therapy. The lecture is intended for a wide range of specialists, residents, and students of medical universities.
About the Authors
V. V. Rassokhin
Pavlov First St. Petersburg State Medical University; St. Petersburg Pasteur Institute
Russian Federation
Russian Federation
Rassokhin Vadim Vladimirovich
St. Petersburg
E. B. Yastrebova
Pavlov First St. Petersburg State Medical University; St. Petersburg Pasteur Institute
Russian Federation
Russian Federation
St. Petersburg
E. O. Gordon
Sverdlovsk Regional Center for the Prevention and Control of AIDS
Russian Federation
Russian Federation
Yekaterinburg
V. Ya. Rozenberg
Republican Clinical Infectious Diseases Hospital
Russian Federation
Russian Federation
St. Petersburg
References
1. Global health sector strategies for HIV, viral hepatitis and sexually transmitted infections, respectively, for 2022–2030. cdn.who.int.media/docs/default-source/hq-hiv, date of access 15.10.2024 (In Russ.).
2. HIV infection in children. Clinical guidelines of the Ministry of Health of the Russian Federation / National Association of Specialists in the Prevention, Diagnosis and Treatment of HIV Infection. 2024, 176 р. (In Russ.)
3. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach / World Health Organization. 2021, 594 р.
4. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv. Accessed (08.01.2023).
5. EACS Guidelines version 11.1, October 2022.
6. Gluhov N.V., Chubrieva S.Yu., Rassohin V.V. Metabolic syndrome in HIV infection. Introduction to the problem. HIV infection and immunosuppression, 2009, Vol. 1, No. 2, рр. 38–49 (In Russ.)
7. Bloetzer C., Bovet P., Suris J.C. et al. Screening for cardiovascular disease risk factors beginning in childhood // Public Health Reviews. 2015. Vol. 36. Р. 9. doi: 10.1186/s40985-015-0011-2.
8. Aleksandrov A.A., Balykova L.A., Bubnova M.G. et al. Prevention of cardiovascular diseases in childhood and adolescence. Russian recommendations. Russian Cardiology Journal, 2012, Vol. 17, No. 6 S1, рр. 1–39 (In Russ.)
9. Certificate «HIV infection in the Russian Federation as of December 31, 2023» Federal Scientific and Methodological Center for the Prevention and Control of AIDS Federal Budgetary Scientific Institution Central Research Institute of Epidemiology of Rospotrebnadzor (In Russ.)
10. Comorbid conditions in HIV infection. Part III. Somatic diseases and disorders. N. A. Belyakov, V. V. Rassokhin. St. Petersburg: Baltic Medical Educational Center, 2019. 252 p.: ill., 252 р. ill. (In Russ.)
11. Newell M.L., Coovadia H., Cortina-Borja M. et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis // Lancet. 2004. Vol. 364, No. 9441. Р. 1236–1243. doi: 10.1016/S0140-6736(04)17140-7.
12. Clinical classification of HIV infection. Appendix to the Instructions for filling out the annual form of state federal statistical observation No. 61 «Information on contingents of patients with HIV infection», approved by Order of the Ministry of Health and Social Development of Russia dated March 17, 2006, No. 166 (In Russ.)
13. Bobkova M.R. HIV Infection cure strategies: basic methodological approaches and difficulties of their implementation. HIV Infection and Immunosuppressive Disorders, 2020, Vol. 12, No. 1, рр. 22–31 (In Russ.). https://doi.org/10.22328/2077-9828-2020-12-1-22-31.
14. Katusiime M.G., Van Zyl G.U., Cotton M.F., Kearney M.F. HIV-1 Persistence in Children during Suppressive ART // Viruses. 2021. Vol. 13, No. 6. Р. 1134. https://doi.org/10.3390/v13061134.
15. Samarina A.V., Yastrebova Ye.B., Lisitsyna Z.N., Dement’Yeva N.Ye., Voropayeva Ye.N., Sizova N.V., Rassokhin V.V., Panteleyeva O.V., Koltsova O.V., Abramova I.A., Dmitriyev A.V., Belyakov N.A. Сase report about successful hiv prevention after transfusion of HIV-infected erythrocyte suspension. HIV Infection and Immunosuppressive Disorders, 2015, Vol. 7, No. 3, рр. 87–96 (In Russ.). https://doi.org/10.22328/2077-9828-2015-7-3-87-96.
16. Fiebig E.W., Wright D.J., Rawal B.D. et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection // AIDS. 2003. Vol. 17. Р. 1871–1879.
17. Leyre L., Kroon E., Vandergeeten C. et al.; RV254/SEARCH010, RV304/SEARCH013, SEARCH011 study groups. Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection // Sci. Transl. Med. 2020. Mar 4; Vol. 12 (533). Р. eaav3491. doi: 10.1126/scitranslmed.aav3491.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. Accessed (08.01.2023).
19. Human immunodeficiency virus — medicine. Еd N. A. Belyakov, A. G. Rahmanovа. St. Petersburg: Baltijskij medicinskij obrazovatel’nyj centr, 2010, 752 р. (In Russ.)
20. Arenas-Pinto A., Grund B., Sharma S. et al. Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial // Clinical Infectious Diseases. 2018. Vol. 67, No. 3. Р. 420–429. doi: 10.1093/cid/ciy051.
21. Ford N., Shubber Z., Pozniak A. et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials // JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015. Vol. 69, No. 4. Р. 422–429. doi:10.1097/QAI.0000000000000606.
22. Gordon E.О., Yastrebova E.B., Podymova A.S. Аdverse events underlying antiretroviral therapy in children with HIV infection. HIV Infection and Immunosuppressive Disorders. 2022. Vol. 14, No. 2, рр. 40–49 (In Russ.). https://doi.org/10.22328/2077-9828-2022-14-2-40-49.
23. Sculier D., Gayet-Ageron A., Battegay M. et al. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study // BMC Infectious Diseases. 2017. Vol. 17. Р. 476. doi:10.1186/s12879-017-2579-2.
24. Briand C., Dollfus C., Faye A. et al. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study // Journal of Antimicrobial Chemotherapy. 2017. Vol. 72, No. 3. Р. 837–843. doi: 10.1093/jac/dkw464.
25. Ciccullo A., Baldin G., Borghi V. et al. Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort // AIDS Research and Human Retroviruses. 2021. Vol. 37, No. 1. Р. 4–10. doi: 10.1089/AID.2020.0078.
26. Carter R.J., Wiener J., Abrams E. J. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis // JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2006. Vol. 41, No. 4. Р. 453–460. doi: 10.1097/01.qai.0000218344.88304.db.
27. Echeverría P., Bonjoch A., Puig J. et al. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia // HIV Medicine. 2017. Vol. 18, No. 10. Р. 782–786. doi: 10.1111/hiv.12530.
28. Molina J.M., Ward D., Brar I. et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial // Lancet HIV. 2018. Vol. 5, No. 7. Р. 357–365. doi: 10.1016/S2352-3018(18)30092-4.
29. Wegzyn C.M., Fredrick L.M., Stubbs R.O. et al. Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants // Journal of the International Association of Providers of AIDS Care (JIAPAC). 2012. Vol. 11, No. 4. Р. 252– 259. doi: 10.1177/1545109712442984.
30. Bienczak A., Denti P., Cook A. et al. Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dosecombination tablets // AIDS. 2017. Vol. 31, No. 7. Р. 905. 3
31. Wu P.Y., Cheng C.Y., Liu C.E. et al. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naive HIV-positive patients receiving non-nucleoside reversetranscriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan // PLoS One. 2017. Vol. 12, No. 2. e0171596. doi: 10.1371/journal.pone.0171596.
32. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand // European Journal of Clinical Pharmacology. 2017. Vol. 73, No. 4. Р. 463–468. doi: 10.1007/s00228-016-2182-2.
33. Federal clinical guidelines (protocols) for the management of children with endocrine diseases / edited by I. I. Dedov and V. A. Peterkova. Moscow: Publishing House Praktika, 2014. 442 р. (In Russ.). ISBN 978-5-89816-133-0.
34. Blázquez D., Ramos-Amador J.T., Saínz T. et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults // BMC Infectious Diseases. 2015. Vol. 15. Р. 119. doi: 10.1186/s12879-015-0853-8.
35. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective // Nature Reviews Drug Discovery. 2003. Vol. 2, No. 10. Р. 812–822. doi: 10.1038/nrd1201.
36. Ulyukin I.M., Orlova E.S., Shuklina A.A. Toxicity of antiretroviral drugs for the treatment of HIV infection. Russian Biomedical Journal, 2020, Vol. 21, No. 1, рр. 819–828 (In Russ.).
37. Beng H., Rakhmanina N., Moudgil A. et al. HIV-Associated CKDs in Children and Adolescents // Kidney International Reports. 2020. Vol. 5, No. 12. Р. 2292–2300. doi: 10.1016/j.ekir.2020.09.001.
38. Osteoporosis / edited by O. M. Lesnyak, L. I. Benevolenskaya. 2nd ed, revised and enlarged. Moscow: Publishing House GEOTAR-Media, 2009. 272 р. (In Russ.).
39. Mallon P.W. HIV and bone mineral density // Current Opinion in Infectious Diseases. 2010. Vol. 23, No. 1. Р. 1–8. doi: 10.1097/QCO.0b013e328334fe9a.
40. Borrás-Blasco J., Navarro-Ruiz A., Borrás C., Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection // Journal of Antimicrobial Chemotherapy. 2008. Vol. 62, No. 5. Р. 879–888. doi: 10.1093/jac/dkn292.
41. Davis C.M., Shearer W.T. Diagnosis and management of HIV drug hypersensitivity // Journal of Allergy and Clinical Immunology. 2008. Vol. 121, No. 4. Р. 826–832. doi: 10.1016/j.jaci.2007.10.021.
42. Smith C., Sabin C.A., Lundgren J.D. et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study // AIDS. 2010. Vol. 24, No. 10. Р. 1537–1548. doi: 10.1097/QAD.0b013e32833a0918.
43. Mataramvura H., Bunders M.J., Duri K. Human immunodeficiency virus and antiretroviral therapy-mediated immune cell metabolic dysregulation in children born to HIV-infected women: potential clinical implications // Front. Immunol. 2023. Vol. 14. Р. 1182217. doi: 10.3389/fimmu.2023.1182217.
44. Kanmogne G.D. HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium // Cells. 2024. Vol. 13, No. 8. Р. 672. https://doi.org/10.3390/cells13080672.
45. Bots M. L., Evans G.W., Tegeler C.H., Meijer R. Carotid Intima-media Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled Trials // Chinese Medical Journal. 2016. Vol. 129, No. 2. Р. 215–226. doi: 10.4103/0366-6999.173500.
46. Sadykova D.I., Galimova L.F., Leontyeva I.V., Slastnikova E.S. Estimation of the thickness of the intima-media complex in children with familial hypercholesterolemia. Russian Bulletin of Perinatology and Pediatrics, 2018, Vol. 63, No. 5, рр. 152–154 (In Russ.). https://doi.org/10.21508/1027-4065-2018-63-5-152-154.
47. Giuliano Ide C., de Freitas S.F., de Souza M., Caramelli B. Subclinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study // Coronary Artery Disease. 2008. Vol. 19, No. 3. Р. 167–172. doi: 10.1097/MCA.0b013e3282f6dffb.
48. McComsey G.A., O’Riordan M., Hazen S.L. et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children // AIDS. 2007. Vol. 21, No. 8. Р. 921–927. doi: 10.1097/QAD.0b013e328133f29c.
49. Kanmogne G.D. HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium. MDPI and ACS Style. Cells. 2024. Vol. 13. Р. 672. https://doi.org/10.3390/cells13080672.
Review
For citations:
Rassokhin V.V., Yastrebova E.B., Gordon E.O., Rozenberg V.Ya. Modern concepts of antiretroviral therapy in children with HIV infection. HIV Infection and Immunosuppressive Disorders. 2025;17(3):9-30. (In Russ.) https://doi.org/10.22328/2077-9828-2025-17-3-9-30
Views:
19
.png)
Email this article 